Disease-modifying antirheumatic non-drug concept codes
Metadata
- Coding system
- SNOMED CT (UK Clinical Edition)
- Coding system release
- 41.0.0
- Organisation
- NHSD Primary Care Domain Refsets
- Codelist ID
- nhsd-primary-care-domain-refsets/dmards_cod
- Version Tag
- 20250912
- Version ID
- 0ca6f348
- Number of codes included
- 54
About
Description
Taken from the `DMARDS_COD` refset published by NHSD. Contains public sector information licensed under the UK Open Government Licence v3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/).
Codelists are developed by a broad community of users for individual study purposes, which may or may not meet the needs of other studies. They should not be thought of as universal definitions of a particular condition.
We don't offer any guarantees about what they do or don't identify. Users should carefully check that any codelist meets their needs, and seek clinical input where appropriate.
| code | term |
|---|---|
| 106511000119106 | Long-term current use of mycophenolate |
| 106521000119104 | Long-term current use of cyclophosphamide |
| 106531000119101 | Long-term current use of penicillamine |
| 106551000119107 | Long-term current use of medicinal gold |
| 106571000119103 | Long-term current use of sulfasalazine |
| 106581000119100 | Long-term current use of cyclosporine |
| 106701000119103 | Long-term current use of leflunomide |
| 1104901000000103 | Hydroxychloroquine-induced retinal toxicity screening |
| 1156666001 | Auranofin therapy |
| 1156667005 | Penicillamine therapy |
| 1179723002 | Administration of tocilizumab |
| 1179729003 | Administration of sarilumab |
| 1287737006 | Sarilumab therapy |
| 140301000119107 | Long-term current use of hydroxychloroquine |
| 140561000119102 | Long-term current use of azathioprine |
| 180229007 | Intravenous injection of Methotrexate |
| 180242007 | Intramuscular gold therapy |
| 180247001 | Intramuscular injection of Methotrexate |
| 25321000000106 | Community disease modifying antirheumatic drug monitoring appointment |
| 309699002 | Intramuscular injection of methotrexate |
| 309700001 | Intravenous injection of methotrexate |
| 311341000000107 | Subcutaneous injection of methotrexate |
| 337871000000109 | Subcutaneous injection of methotrexate |
| 36991000000102 | Community DMARD monitoring appointment |
| 37001000000108 | Community DMARD monitoring appointment |
| 402428008 | Accelerated rheumatoid nodulosis caused by methotrexate |
| 439824001 | Subcutaneous injection of methotrexate |
| 44671000000103 | Disease modifying antirheumatic drug monitoring |
| 518391000000109 | Disease modifying antirheumatic drug therapy initiated |
| 581000119100 | Long term methotrexate user |
| 61251000119108 | Long-term current use of tacrolimus |
| 672601000119103 | Long-term current use of auranofin |
| 713518008 | Mycophenolate therapy |
| 713550003 | Cyclophosphamide therapy |
| 713551004 | Azathioprine therapy |
| 715121000000104 | Community disease modifying antirheumatic drug monitoring administration |
| 717041000000104 | Community disease modifying antirheumatic drug monitoring appointment |
| 717837005 | Leflunomide therapy |
| 717856000 | Sulfasalazine therapy |
| 723945004 | Cyclosporine therapy |
| 724160005 | Tacrolimus therapy |
| 726605004 | Medicinal gold therapy |
| 782709005 | Hydroxychloroquine therapy |
| 803771000000101 | Community disease modifying antirheumatic drug monitoring call |
| 803821000000107 | Community disease modifying antirheumatic drug monitoring first letter |
| 803841000000100 | Community disease modifying antirheumatic drug monitoring second letter |
| 803861000000104 | Community disease modifying antirheumatic drug monitoring third letter |
| 804041000000107 | Community disease modifying antirheumatic drug monitoring invitation |
| 804131000000104 | Community disease modifying antirheumatic drug monitoring verbal invitation |
| 804141000000108 | Community DMARD (disease modifying antirheumatic drug) monitoring verbal invitation |
| 804191000000103 | Community disease modifying antirheumatic drug monitoring telephone invitation |
| 910111000000106 | Mixed strength methotrexate prescribing warning |
| 910131000000103 | Mixed strength methotrexate prescribing appropriate |
| 910141000000107 | Mixed strength methotrexate prescribing appropriate |